Traders assign an 82% probability to no new COVID variant of concern before 2027 because SARS-CoV-2 continues to evolve primarily through Omicron sublineages without triggering the formal VOC threshold. As of late May 2026, neither the WHO nor ECDC has designated any variant of concern, with recent lineages such as BA.3.2, XFG, and NB.1.8.1 classified only as variants of interest or under monitoring due to limited impact on severity or vaccine effectiveness. Ongoing genomic surveillance shows steady circulation and incremental mutations, yet population immunity from prior infections and updated vaccines has kept disease outcomes stable. This pattern of gradual adaptation without sudden jumps in transmissibility or immune escape supports the current market pricing, though continued monitoring through 2026 could still identify shifts if a more divergent strain emerges.